AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$MYO

Kovelman Harry sold $20K of MYO

Kovelman Harry (Chief Medical Officer) sold 15,488 shares of MYOMO, INC. (MYO) at $1.27 on 2026-09-11.

Original reporting
SEC EDGAR · Kovelman Harry
Published Sep 14, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MYO
Bearish
low confidence
Mentioned
$MYO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYOBearishLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly, but may be noted by short-term traders.

02

Market read

Small insider sell with limited trading relevance.

03

What to watch

Potential upcoming clinical data or corporate events not disclosed.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filing reports insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$MYOBearishLow confidence
Context

Chief Medical Officer Harry Kovelman sold 15,488 shares for $19,683.70 on 2026-09-11.

Expected impact

Potential short-term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Sale size is small relative to total holdings and market cap; no material impact expected.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

U.S. market only; negligible regional effect.

Global

None

Counterpoint

What could challenge this read

Insider may be reallocating capital; could signal confidence in future prospects.

Key entities

  • Officer
    Harry Kovelman

    Chief Medical Officer of Myomo, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MYO insider trading history →

Related articles

AUG 9
$MYOMedAI 8/10

Myomo Q2 Earnings Call Highlights

Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.

yahoo.com6 min
AUG 5
$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guidance to $45-47 million Conference call beg

SEC EDGAR 8-K6 min
JUN 16
$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

rttnews.com6 min
JUN 11
$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

rttnews.com7 min